🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Brincidofovir

    Jazz Pharmaceuticals Ireland Limited

    Adenovirus Disease

    phase 2 small molecule completed

    1 trial

  2. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial

  3. Budesonide

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  4. Budesonide + Azelastine

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  5. Budigalimab, Placebo for Budigalimab (ABBV-181) - 0.9% Sodium Chloride or DILUENT, ABBV-382, Placebo for ABBV-382 Solution for Infusion

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  6. C16G2

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    3 trials

  7. C16G2 Gel

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial

  8. C16G2 Rinse

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial

  9. C16G2 Strip

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial

  10. C16G2 Varnish

    Armata Pharmaceuticals

    Dental Caries

    phase 2 small molecule completed

    1 trial

  11. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Australia Pty Ltd

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  12. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  13. CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  14. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  15. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  16. CBD 400 mg

    Jazz Pharmaceuticals Ireland Limited

    Opiate Addiction

    phase 2 small molecule completed

    1 trial

  17. CBD Oral Solution

    Jazz Pharmaceuticals Ireland Limited

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  18. CBD Oral Solution (eCBD system Target)

    Jazz Pharmaceuticals Ireland Limited

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  19. CBD, ABILIFY 1 mg/ml oral solution, Aripiprazolo Aurobindo 15 mg compresse, ARIPIPRAZOLE , Composition (%w/V): Sesame oil, refined 90,00, Ethanol, anhydrous 7,91, Sucralose 0,05, DL-alfa-tocopheryl acetate 0,18, Raspberry flavor 0,02.

    Fondazione Telethon ETS

    Substance-Induced Psychosis

    phase 2 small molecule active

    1 trial

  20. CE-Iohexol

    LIGAND PHARMACEUTICALS INC

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  21. CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

    Chiesi Farmaceutici S.p.A

    Mild to moderate asthma

    phase 2 small molecule active

    1 trial

  22. CHF6001 DPI

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 2 small molecule active

    1 trial

  23. CHRONVAC-C®

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule active

    1 trial

  24. CID-103

    CASI Pharmaceuticals

    Chronic Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources